1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-64.
2. Zauber AG. The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci. 2015;60(3):681-91.
3. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, Jr., Garcia FAR, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Jama. 2016;315(23):2564-75.
4. Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015;25(3):208-13.e1.
5. D'Andrea E, Ahnen DJ, Sussman DA, Najafzadeh M. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. Cancer Med. 2020;9(2):824-36.
6. Nielson CM, Vollmer WM, Petrik AF, Keast EM, Green BB, Coronado GD. Factors Affecting Adherence in a Pragmatic Trial of Annual Fecal Immunochemical Testing for Colorectal Cancer. J Gen Intern Med. 2019;34(6):978-85.
7. Subramanian S, Tangka FK, Hoover S, Beebe MC, DeGroff A, Royalty J, et al. Costs of planning and implementing the CDC's Colorectal Cancer Screening Demonstration Program. Cancer. 2013;119 Suppl 15:2855-62.
8. Walsh JM, Salazar R, Nguyen TT, Kaplan C, Nguyen LK, Hwang J, et al. Healthy colon, healthy life: a novel colorectal cancer screening intervention. Am J Prev Med. 2010;39(1):1-14.
9. Coronado GD, Golovaty I, Longton G, Levy L, Jimenez R. Effectiveness of a clinic-based colorectal cancer screening promotion program for underserved Hispanics. Cancer. 2011;117(8):1745-54.
10. Church TR, Yeazel MW, Jones RM, Kochevar LK, Watt GD, Mongin SJ, et al. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. J Natl Cancer Inst. 2004;96(10):770-80.
11. Myers RE, Sifri R, Hyslop T, Rosenthal M, Vernon SW, Cocroft J, et al. A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer. 2007;110(9):2083-91.
12. Gupta S, Lieberman D. Screening and Surveillance Colonoscopy and COVID-19: Avoiding More Casualties. Gastroenterology. 2020;159(4):1205-8.
13. Issaka RB, Somsouk M. Colorectal Cancer Screening and Prevention in the COVID-19 Era. JAMA Health Forum. 2020;1(5):e200588-e.
14. Ateev Mehrotra MC, David Linetsky, Hilary Hatch, and David Cutler. The Commonwealth Fund. 2020. [cited 2021 2/9/2021]. Available from: https://www.commonwealthfund.org/publications/2020/apr/impact-covid-19-outpatient-visits.
15. Mast CaMdR, Alejandro COVID-19 weekly volumes for preventive cancer screenings for breast, colon, and cervical cancer are 86%-94% lower than 2017-2019 historical averages. Epic Health Research Network: EHRN Journal; 2020 [Available from: https://ehrn.org/articles/delays-in-preventive-cancer-screenings-during-covid-19-pandemic/.
16. Nielson CM, Petrik AF, Jacob L, Vollmer WM, Keast EM, Schneider JL, et al. Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial. Cancer Med. 2018;7(9):4781-90.
17. Pham R, Cross S, Fernandez B, Corson K, Dillon K, Yackley C, et al. "Finding the Right FIT": Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics. J Am Board Fam Med. 2017;30(5):632-44.
18. Bharti B, May FFP, Nodora J, Martínez ME, Moyano K, Davis SL, et al. Diagnostic colonoscopy completion after abnormal fecal immunochemical testing and quality of tests used at 8 Federally Qualified Health Centers in Southern California: Opportunities for improving screening outcomes. Cancer. 2019;125(23):4203-9.
19. Coronado GD, Green BB, West, II, Schwartz MR, Coury JK, Vollmer WM, et al. Direct-to-member mailed colorectal cancer screening outreach for Medicaid and Medicare enrollees: Implementation and effectiveness outcomes from the BeneFIT study. Cancer. 2020;126(3):540-8.
20. Coury JK, Schneider JL, Green BB, Baldwin LM, Petrik AF, Rivelli JS, et al. Two Medicaid health plans' models and motivations for improving colorectal cancer screening rates. Transl Behav Med. 2020;10(1):68-77.
21. Meenan RT, Coronado GD, Petrik A, Green BB. A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics. Prev Med. 2019;120:119-25.
22. Meenan RT, Baldwin LM, Coronado GD, Schwartz M, Coury J, Petrik AF, et al. Costs of Two Health Insurance Plan Programs to Mail Fecal Immunochemical Tests to Medicare and Medicaid Plan Members. Popul Health Manag. 2020.
23. Tangka FK, Subramanian S, Beebe MC, Hoover S, Royalty J, Seeff LC. Clinical costs of colorectal cancer screening in 5 federally funded demonstration programs. Cancer. 2013;119 Suppl 15(0 15):2863-9.
24. Davis MM, Renfro S, Pham R, Hassmiller Lich K, Shannon J, Coronado GD, et al. Geographic and population-level disparities in colorectal cancer testing: A multilevel analysis of Medicaid and commercial claims data. Prev Med. 2017;101:44-52.
25. Davis MM, Nambiar S, Mayorga ME, Sullivan E, Hicklin K, O'Leary MC, et al. Mailed FIT (fecal immunochemical test), navigation or patient reminders? Using microsimulation to inform selection of interventions to increase colorectal cancer screening in Medicaid enrollees. Preventive medicine. 2019;129s:105836.
26. Fagnan LJ, Morris C, Shipman SA, Holub J, King A, Angier H. Characterizing a practice-based research network: Oregon Rural Practice-Based Research Network (ORPRN) survey tools. J Am Board Fam Med. 2007;20(2):204-19.
27. Nagykaldi Z, Mold JW, Robinson A, Niebauer L, Ford A. Practice facilitators and practice-based research networks. J Am Board Fam Med. 2006;19(5):506-10.
28. Network ORP-bR. Oregon Rural Practice-based Research Network: What We Do: Oregon Health & Science University; 2021 [cited 2021. Available from: https://www.ohsu.edu/oregon-rural-practice-based-research-network.
29. Health OOoR. Spreadsheet of Oregon Zip Codes, Towns, Cities and Service Areas and their ORH Urban/Rural/Frontier Designation. In: Designation.xls OZCTCaSAatOURF, editor. 2019. p. Spreadsheet.
30. Cox NJ. TABCOUNT: Stata module to tabulate frequencies, with zeros explicit Statistical Software Components S429501 Boston College Department of Economics; 2002 [updated revised 24 Sep 2004. Available from: https://ideas.repec.org/c/boc/bocode/s429501.html.
31. Chiang TH, Chuang SL, Chen SL, Chiu HM, Yen AM, Chiu SY, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147(6):1317-26.
32. Foutz J AS, Garfield R. The Role of Medicaid in Rural America. Issue Brief. The Henry J. Kaiser Family Foundation; 2017 Apr 25, 2017.
33. Kurani SS, McCoy RG, Lampman MA, Doubeni CA, Finney Rutten LJ, Inselman JW, et al. Association of Neighborhood Measures of Social Determinants of Health With Breast, Cervical, and Colorectal Cancer Screening Rates in the US Midwest. JAMA Netw Open. 2020;3(3):e200618.
34. Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(12):1645-58.
35. Jager M, Demb J, Asghar A, Selby K, Mello EM, Heskett KM, et al. Mailed Outreach Is Superior to Usual Care Alone for Colorectal Cancer Screening in the USA: A Systematic Review and Meta-analysis. Dig Dis Sci. 2019;64(9):2489-96.
36. Coronado GD. Who Is Reached With Clinic In-Reach and Outreach Strategies to Promote Colorectal Cancer Screening? American Journal of Public Health. 2020;110(4):437-9.
37. Castañeda SF, Bharti B, Espinoza-Giacinto RA, Sanchez V, O'Connell S, Muñoz F, et al. Evaluating Two Evidence-Based Intervention Strategies to Promote CRC Screening Among Latino Adults in a Primary Care Setting. J Racial Ethn Health Disparities. 2018;5(3):530-5.
38. Hudson SV, Ferrante JM, Ohman-Strickland P, Hahn KA, Shaw EK, Hemler J, et al. Physician recommendation and patient adherence for colorectal cancer screening. J Am Board Fam Med. 2012;25(6):782-91.
39. Gilbert A, Kanarek N. Colorectal cancer screening: physician recommendation is influential advice to Marylanders. Prev Med. 2005;41(2):367-79.
40. Subramanian S, Tangka FKL, Hoover S, Cole-Beebe M, Joseph D, DeGroff A. Comparison of Program Resources Required for Colonoscopy and Fecal Screening: Findings From 5 Years of the Colorectal Cancer Control Program. Prev Chronic Dis. 2019;16:E50.
41. Davis MM, Freeman M, Shannon J, Coronado GD, Stange KC, Guise JM, et al. A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States - How, what and when? BMC cancer. 2018;18(1):40.
42. Brtnikova M, Crane LA, Allison MA, Hurley LP, Beaty BL, Kempe A. A method for achieving high response rates in national surveys of U.S. primary care physicians. PLoS One. 2018;13(8):e0202755.